ClinicalTrials.gg
CompletedNCT01642407Updated Feb 1, 2021Results posted

Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension

A Phase 4 interventional study of Sildenafil in Pulmonary Arterial Hypertension and Hypertension, Pulmonary, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in Japan. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
17th of 18
6 · median 23
Started
2012
the only one that year
Phase 4
6 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 17th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 4, and was the 15th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.

Sildenafil was approved by the European Commission for the treatment of PAH in pediatric patients in May 2011, making it the first agent to be approved for the treatment of children with PAH. The approval was based on the largest placebo-controlled study to be conducted in this population. The recommended dose in pediatric patients aged 1 year to 17 years old is 10 mg TID in patients ≤ 20 kg and 20 mg TID for patients > 20 kg. Higher doses are not recommended in pediatrics patients.

This study is an open-label, multi-center study to investigate safety, efficacy and pharmacokinetics of sildenafil citrate in Japanese pediatric patients with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension
  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects weighing ≥8 kg.
  • Subjects who have symptomatic pulmonary arterial hypertension due to one of the following conditions:
  • Idiopathic pulmonary arterial hypertension; or
  • Heritable pulmonary arterial hypertension; or
  • Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts. If the defect(s) is repaired, the subject's condition should be stabilized hemodynamically; or
  • Pulmonary arterial hypertension associated with d-transposition of the great arteries repaired within the first 30 days of life; or
  • Pulmonary arterial hypertension in subjects who have undergone surgical repair of other congenital heart lesions and the condition should be stabilized hemodynamically and do not have residual left-sided heart disease.
  • Subjects with a mean pulmonary artery pressure ≥25 mmHg at rest, PCWP ≤15 mmHg, and PVRI ≥3 Wood units x m2. If PCWP is not available, then mean LA pressure ≤15 mmHg or LVEDP ≤15 mmHg in the absence of left atrial obstruction.

Exclusion criteria

Exclusion Criteria:

  • Left-sided heart disease.
  • Subjects with Down syndrome.
  • Subjects with Obstructive Sleep Apnea, regardless of treatment status.
  • Pericardial constriction.
  • Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation.
  • Acutely decompensated heart failure within previous 30 days from screening.
  • Subjects who have had an atrial septostomy within previous 6 months of screening.
  • Subjects with hemodynamic instability or hypo- or hypertension at screening.
  • Subjects with a history of stroke, myocardial infarction or life threatening arrhythmia within 6 months of screening.
  • Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital Capacity ≤60% of normal) or history of severe lung disease.
  • Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
  • Subjects with history of pulmonary embolism.
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
  • Subjects who are known to be positive.
  • Subjects with impairment of renal function (serum creatinine >2.5 × ) or hepatic function ( and/or AST >3 × ULN; and/or ≥2 mg/dL). Hematological abnormalities (e.g., severe anemia, \<10 g/dL, leukopenia, WBC \<2500/µL).
  • Subjects with severe hepatic dysfunction ( classification C).
  • Change in class of medication for CHF or PAH within the 10 days prior to qualifying right heart catheterization.
  • Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form.
  • Subjects taking chronic arginine supplementation.
  • Subjects who have received parenteral inotropic medication or parenteral vasodilators within 30 days of Day 1.
  • Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome P450 3A4 inhibitors.
  • Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1 are excluded. Subjects receiving an endothelin antagonist,PED5 inhibitor or, prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except for beraprost.
  • Pregnant females; breastfeeding females; males and females of not using highly effective or not agreeing to continue highly effective contraception for at least 28 days after last dose of product.
  • Current or past illicit drug use or alcoholism excepting if abstinence can be documented for ≥1 year.
  • Participation in another clinical trial of an investigational drug or device (including placebo) within 30 days of screening for entry into the present study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Sildenafil

    Drug: Sildenafil

Interventions

  • Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16

    PVRI equals pulmonary vascular resistance (PVR) times body surface area (BSA) (PVRI = PVR\*BSA). PVR is the resistance to blood flow through the pulmonary circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

    Time frame: Baseline, Week 16

  2. Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 16

    It was a hemodynamic parameter and measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.

    Time frame: Baseline, Week 16

  3. Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 4

    WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

    Time frame: Baseline, Week 4

  4. Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 8

    WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

    Time frame: Baseline, Week 8

  5. Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 16

    WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 16

    BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.

    Time frame: Baseline, Week 16

  7. Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 16

    NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Weeks 28, 40, 52, 64, 76, 88, 100, 112 and 124

    WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

  2. Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 52 and End of Treatment (EOT)

    BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.

    Time frame: Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)

  3. Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 52 and End of Treatment (EOT)

    NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

    Time frame: Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)

  4. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-serious AEs.

    Time frame: Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)

  5. Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.

    Time frame: Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)

  6. Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

    BP measurement is recorded as supine and sitting systolic and diastolic systemic blood pressure: 1) Systolic blood pressure when heart is contracting and it is the maximum arterial pressure during contraction of left ventricle. 2) Diastolic BP when heart is relaxing and it is the minimum arterial pressure during relaxation and dilation of ventricles. Only those categories in which at least 1 participant had data were reported.

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

  7. Change From Baseline in Heart Rate at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

    Only those categories in which at least 1 participant had data were reported.

    Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

  8. Number of Participants With Laboratory Abnormalities

    Laboratory abnormality criteria: Hematology (hemoglobin, hematocrit, red blood cell count \[less than {\<}\]0.8\*lower limit of normal \[LLN\]; platelets \<0.5\*LLN, greater than \[\>\]1.75\*upper limit of normal \[ULN\], white blood cells \<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN, \>1.2\*ULN, eosinophils, basophils, monocytes \>1.2\*ULN); liver function (total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein, albumin \<0.8\*LLN, \>1.2\*ULN); renal (creatinine, blood urea nitrogen \>1.3\*ULN); electrolytes (sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride \<0.9\*LLN, \>1.1\*ULN; other (glucose \<0.6\*LLN or \>1.5\*ULN ); urinalysis (dipstick) urine glucose, urine protein, urine blood/Hemoglobin, \[greater than or equal to {\>=}1\].

    Time frame: Baseline up-to End of treatment (maximum duration of treatment: 119.6 weeks)

  9. Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities

    Criteria for clinically significant abnormality in ECG parameters: Maximum corrected QT interval (QTc) from 450 millisecond (msec) to less than (\<) 480 msec, Maximum QTcB interval (Bazett's Correction) from 450 msec to \<480 msec, Maximum QTcF interval (Fredericia's Correction) from 450 msec to \<480 msec, maximum QTc interval increase from baseline of 30 msec to \<60 msec and \>=60 msec.

    Time frame: Screening, Week 16, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)

  10. Number of Participants With Ocular Examination Abnormalities

    Ocular examination measures included external examination of the eye, funduscopy, assessments of visual acuity, and color vision. Ocular examination findings were considered abnormal based on investigator's decision.

    Time frame: Screening up to end of treatment (maximum duration of treatment: 119.6 weeks)

  11. Change From Baseline in Pulmonary Artery Systolic and Diastolic Pressure at Week 16

    Time frame: Baseline, Week 16

  12. Change From Baseline in Systemic Artery Systolic and Diastolic Pressure at Week 16

    Time frame: Baseline, Week 16

  13. Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16

    The resistance to blood flow through the pulmonary circulation is known as PVR. It is largely influenced by the caliber of the pulmonary arteries and capillaries and was measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

    Time frame: Baseline, Week 16

  14. Change From Baseline in Right Atrial Pressure (RAP) at Week 16

    RAP is the blood pressure in the right atrium of the heart. It reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system. RAP was measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.

    Time frame: Baseline, Week 16

  15. Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16

    PCWP was measured by pulmonary artery catheterization and provided an indirect measure of left atrial pressure.

    Time frame: Baseline, Week 16

  16. Change From Baseline in Cardiac Output (CO) at Week 16

    Cardiac output is simply the amount of blood pumped by the heart per minute.

    Time frame: Baseline, Week 16

  17. Change From Baseline in Cardiac Index (CI) at Week 16

    Cardiac index is a hemodynamic parameter that relates the cardiac output from left ventricle in one minute to BSA, thus relating heart performance to the size of the individual. CI was calculated as cardiac output in systemic circulation divided by BSA.

    Time frame: Baseline, Week 16

  18. Change From Baseline in Systemic Vascular Resistance (SVR) at Week 16

    The resistance to blood flow through the systemic circulation is known as SVR. This can be used in measuring blood pressure, blood flow and cardiac function and measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

    Time frame: Baseline, Week 16

  19. Change From Baseline in Systemic Vascular Resistance Index (SVRI) at Week 16

    SVRI equals systemic vascular resistance (SVR) times BSA. SVR is the resistance to blood flow through the systemic circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

    Time frame: Baseline, Week 16

  20. Change From Baseline in Mixed Venous Oxygen Saturation (SvO2) at Week 16

    SvO2 is the percentage of mixed venous oxygen (amount of oxygen bound to hemoglobin in venous blood). Change from baseline in percentage of mixed venous oxygen was reported in this outcome measure.

    Time frame: Baseline, Week 16

  21. Change From Baseline in Arterial Oxygen Saturation (SaO2) at Week 16

    SaO2 is the percentage of arterial oxygen (amount of oxygen bound to hemoglobin in arterial blood). Change from baseline in percentage of arterial oxygen was reported in this outcome measure.

    Time frame: Baseline, Week 16

Other outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sildenafil and UK-103,320

    UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  2. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Sildenafil and UK-103,320

    UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sildenafil and UK-103,320

    UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  4. Terminal Half Life (t1/2) of Sildenafil and UK-103,320

    Terminal half-life is the time measured for the plasma concentration to decrease by one half of its original concentration. UK-103,320 was a main metabolite of sildenafil and was produced by cytochrome P450 3A4.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  5. Apparent Oral Clearance (CL/F) of Sildenafil

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  6. Apparent Volume of Distribution (Vz/F) of Sildenafil

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16

  7. Change From Baseline in Ratio of Acceleration Time to Ejection Time (AcT/ET) at Week 16

    Acceleration time and ejection time are quantitative Doppler parameters and ratio of acceleration time to ejection time is a useful tool to evaluate the severity of aortic stenosis.

    Time frame: Baseline, Week 16

  8. Change From Baseline in Right Ventricular Tei Index at Week 16

    The right ventricular Tei Index is an index of myocardial performance. It is defined as the sum of isovolumic contraction time and isovolumic relaxation time divided by the ejection time.

    Time frame: Baseline, Week 16

  9. Change From Baseline in Right Ventricular Size at Week 16

    Time frame: Baseline, Week 16

  10. Change From Baseline in Tricuspid Valve Annulus Size at Week 16

    The tricuspid valve lies between the right atrium and the right ventricle and is placed in a more apical position than the mitral valve. The annulus separates the right atrium from the right ventricle. Change from baseline in tricuspid valve annulus size (in cm) was reported in this outcome measure.

    Time frame: Baseline, Week 16

  11. Change From Baseline in Tricuspid Regurgitation - Pressure Gradient (TR-PG) Peak at Week 16

    Tricuspid regurgitation (insufficiency) is the failure of the tricuspid valve to close properly during systole, leading to the leaking of blood from the right ventricle into the right atrium. Change from baseline in TR-PG peak (in mmHg) was reported in this outcome measure.

    Time frame: Baseline, Week 16

  12. Change From Baseline in Pulmonary Regurgitation - Pressure Gradient (PR-PG) End-Diastole at Week 16

    Pulmonary regurgitation (PR) or insufficiency is a valvular heart disease characterized by an incomplete closure of the pulmonary valve leading to a diastolic reflux into the right ventricle. Change from baseline in PR-PG end-diastole (in mmHg) was reported in this outcome measure.

    Time frame: Baseline, Week 16

  13. Number of Participants With Pericardial Effusion

    Pericardial effusion is the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.

    Time frame: Baseline up to Week 16

  14. Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 16

    Tricuspid annular plane systolic excursion is a parameter depicting global right ventricular function. Change from baseline in TAPSE (in cm) was reported in this outcome measure.

    Time frame: Baseline, Week 16

07

Results

Posted Apr 4, 2017

Participant flow

Part 1 (Screening Till Week 16)
Participant flow — Part 1 (Screening Till Week 16)
MilestoneSildenafil
Started6
Completed3
Not completed3
Withdrew: Insufficient clinical response3
Part 2(Week17 to Maximum of 119.6 Weeks)
Participant flow — Part 2(Week17 to Maximum of 119.6 Weeks)
MilestoneSildenafil
Started3
Completed1
Not completed2
Withdrew: Coil embolization1
Withdrew: Change of treatment plan1

Outcome measures

PrimaryChange From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16

PVRI equals pulmonary vascular resistance (PVR) times body surface area (BSA) (PVRI = PVR\*BSA). PVR is the resistance to blood flow through the pulmonary circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

Time frame:
Baseline, Week 16
Reported as:
Mean · wood units*meter^2
Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16
wood units*meter^2Sildenafil
Baseline18.567 ± 11.7629
Change at Week 16-4.113 ± 6.3770
PrimaryChange From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 16

It was a hemodynamic parameter and measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.

Time frame:
Baseline, Week 16
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 16
millimeter of mercury (mmHg)Sildenafil
Baseline58.5 ± 22.94
Change at Week 16-6.5 ± 15.15
PrimaryChange From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 4

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

Time frame:
Baseline, Week 4
Reported as:
Number · participants
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 4
participantsSildenafil
Baseline: Class I2 ± 0.58
Baseline: Class II3 ± 0.58
Baseline: Class III1
Baseline: Class IV0
Week 4: Improved1
Week 4: No change5
Week 4: Worsened0
PrimaryChange From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 8

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

Time frame:
Baseline, Week 8
Reported as:
Number · participants
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 8
participantsSildenafil
Improved1 ± 0.71
No change4
Worsened0
PrimaryChange From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 16

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

Time frame:
Baseline, Week 16
Reported as:
Number · participants
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 16
participantsSildenafil
Improved1 ± 0.71
No change3
Worsened0
PrimaryChange From Baseline in Brain Natriuretic Peptide (BNP) at Week 16

BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.

Time frame:
Baseline, Week 16
Reported as:
Mean · picogram per milliliter
Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 16
picogram per milliliterSildenafil
Baseline132.62 ± 135.080
Change at Week 16-64.10 ± 129.638
PrimaryChange From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 16

NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

Time frame:
Baseline, Week 16
Reported as:
Mean · picogram per milliliter
Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 16
picogram per milliliterSildenafil
Baseline843.03 ± 1120.900
Change at Week 16-546.85 ± 1107.621
SecondaryChange From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Weeks 28, 40, 52, 64, 76, 88, 100, 112 and 124

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported.

Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Reported as:
Count of participants · Participants
Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Weeks 28, 40, 52, 64, 76, 88, 100, 112 and 124
ParticipantsSildenafil
Baseline: Class I1
Baseline: Class II2
Baseline: Class III0
Baseline: Class IV0
Week 28: Improved1
Week 28: No Change2
Week 28: Worsened0
Week 40: Improved1
Week 40: No Change2
Week 40: Worsened0
Week 52: Improved1
Week 52: No Change2
Week 52: Worsened0
Week 64: Improved1
Week 64: No Change1
Week 64: Worsened0
Week 76: Improved1
Week 76: No Change0
Week 76: Worsened1
Week 88: Improved1
Week 88: No Change0
Week 88: Worsened0
Week 100: Improved1
Week 100: No Change0
Week 100: Worsened0
Week 112: Improved1
Week 112: No Change0
Week 112: Worsened0
Week 124: Improved1
Week 124: No Change0
Week 124:Worsened0
SecondaryChange From Baseline in Brain Natriuretic Peptide (BNP) at Week 52 and End of Treatment (EOT)

BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation.

Time frame:
Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Reported as:
Mean · picograms per milliliter
Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 52 and End of Treatment (EOT)
picograms per milliliterSildenafil
Baseline100.17 ± 151.478
Change at Week 52-85.17 ± 155.088
Change at EoT-85.17 ± 155.088
SecondaryChange From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 52 and End of Treatment (EOT)

NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

Time frame:
Baseline, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Reported as:
Mean · picograms per milliliter
Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 52 and End of Treatment (EOT)
picograms per milliliterSildenafil
Baseline841.73 ± 1323.533
Change at Week 52-754.90 ± 1335.370
Change at EoT-754.90 ± 1335.370
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-serious AEs.

Time frame:
Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsSildenafil
AEs6
SAEs0
SecondaryNumber of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.

Time frame:
Baseline upto 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsSildenafil
AEs3
SAEs0
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure (BP) at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

BP measurement is recorded as supine and sitting systolic and diastolic systemic blood pressure: 1) Systolic blood pressure when heart is contracting and it is the maximum arterial pressure during contraction of left ventricle. 2) Diastolic BP when heart is relaxing and it is the minimum arterial pressure during relaxation and dilation of ventricles. Only those categories in which at least 1 participant had data were reported.

Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Reported as:
Mean · mmHg
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
mmHgSildenafil
Baseline: Supine Systolic BP95.4 ± 13.41
Baseline: Supine Diastolic BP55.8 ± 10.87
Baseline: Sitting Systolic BP110.0
Baseline: Sitting Diastolic BP60.0
Change at Week 4: Supine Systolic BP5.6 ± 9.91
Change at Week 4: Supine Diastolic BP1.6 ± 13.65
Change at Week 4: Sitting Systolic BP16.0
Change at Week 4: Sitting Diastolic BP23.0
Change at Week 8: Supine Systolic BP7.8 ± 14.93
Change at Week 8: Supine Diastolic BP2.3 ± 12.28
Change at Week 8: Sitting Systolic BP-6.0
Change at Week 8: Sitting Diastolic BP-3.0
Change at Week 16: Supine Systolic BP7.7 ± 17.62
Change at Week 16: Supine Diastolic BP-1.3 ± 12.22
Change at Week 16: Sitting Systolic BP8.0
Change at Week 16: Sitting Diastolic BP10.0
Change at Week 28: Supine Systolic BP7.0 ± 19.31
Change at Week 28: Supine Diastolic BP1.7 ± 9.29
Change at Week 40: Supine Systolic BP-7.5 ± 3.54
Change at Week 40: Supine Diastolic BP2.0 ± 0.00
Change at Week 52: Supine Systolic BP2.0 ± 15.56
Change at Week 52: Supine Diastolic BP10.0 ± 5.66
Change at Week 64: Supine Systolic BP1.0
Change at Week 64: Supine Diastolic BP8.0
Change at Week 76: Supine Systolic BP-13.0
Change at Week 76: Supine Diastolic BP3.0
SecondaryChange From Baseline in Heart Rate at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124

Only those categories in which at least 1 participant had data were reported.

Time frame:
Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Heart Rate at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, 100, 112 and 124
beats per minute (bpm)Sildenafil
Baseline: Supine Heart rate100.2 ± 15.91
Baseline: Sitting Heart rate96.0
Change at Week 4: Supine Heart rate-1.0 ± 12.08
Change at Week 4: Sitting Heart rate-22.0
Change at Week 8: Supine Heart rate-0.5 ± 9.11
Change at Week 8: Sitting Heart rate0.0
Change at Week 16: Supine Heart rate3.0 ± 28.69
Change at Week 16: Sitting Heart rate4.0
Change at Week 28: Supine Heart rate6.7 ± 14.36
Change at Week 40: Supine Heart rate10.0 ± 16.97
Change at Week 52: Supine Heart rate-2.0 ± 11.31
Change at Week 64: Supine Heart rate17.0
Change at Week 76: Supine Heart rate-8.0
SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory abnormality criteria: Hematology (hemoglobin, hematocrit, red blood cell count \[less than {\<}\]0.8\*lower limit of normal \[LLN\]; platelets \<0.5\*LLN, greater than \[\>\]1.75\*upper limit of normal \[ULN\], white blood cells \<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN, \>1.2\*ULN, eosinophils, basophils, monocytes \>1.2\*ULN); liver function (total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein, albumin \<0.8\*LLN, \>1.2\*ULN); renal (creatinine, blood urea nitrogen \>1.3\*ULN); electrolytes (sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride \<0.9\*LLN, \>1.1\*ULN; other (glucose \<0.6\*LLN or \>1.5\*ULN ); urinalysis (dipstick) urine glucose, urine protein, urine blood/Hemoglobin, \[greater than or equal to {\>=}1\].

Time frame:
Baseline up-to End of treatment (maximum duration of treatment: 119.6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsSildenafil
Number of Participants With Laboratory Abnormalities4
SecondaryNumber of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities

Criteria for clinically significant abnormality in ECG parameters: Maximum corrected QT interval (QTc) from 450 millisecond (msec) to less than (\<) 480 msec, Maximum QTcB interval (Bazett's Correction) from 450 msec to \<480 msec, Maximum QTcF interval (Fredericia's Correction) from 450 msec to \<480 msec, maximum QTc interval increase from baseline of 30 msec to \<60 msec and \>=60 msec.

Time frame:
Screening, Week 16, Week 52 and End of treatment (maximum duration of treatment: 119.6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
ParticipantsSildenafil
Screening4
Week 165
Week 521
End of Treatment1
SecondaryNumber of Participants With Ocular Examination Abnormalities

Ocular examination measures included external examination of the eye, funduscopy, assessments of visual acuity, and color vision. Ocular examination findings were considered abnormal based on investigator's decision.

Time frame:
Screening up to end of treatment (maximum duration of treatment: 119.6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Ocular Examination Abnormalities
ParticipantsSildenafil
Number of Participants With Ocular Examination Abnormalities0
SecondaryChange From Baseline in Pulmonary Artery Systolic and Diastolic Pressure at Week 16
Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Artery Systolic and Diastolic Pressure at Week 16
mmHgSildenafil
Baseline: Systolic Pressure82.5 ± 35.51
Baseline: Diastolic Pressure42.0 ± 18.19
Change at Week 16: Systolic Pressure-9.8 ± 18.01
Change at Week 16: Diastolic Pressure-3.5 ± 13.99
SecondaryChange From Baseline in Systemic Artery Systolic and Diastolic Pressure at Week 16
Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Systemic Artery Systolic and Diastolic Pressure at Week 16
mmHgSildenafil
Baseline: Systolic Pressure95.3 ± 15.20
Baseline: Diastolic Pressure60.2 ± 19.30
Change at Week 16: Systolic Pressure0.3 ± 10.21
Change at Week 16: Diastolic Pressure-1.5 ± 14.25
SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16

The resistance to blood flow through the pulmonary circulation is known as PVR. It is largely influenced by the caliber of the pulmonary arteries and capillaries and was measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

Time frame:
Baseline, Week 16
Reported as:
Mean · Wood units
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16
Wood unitsSildenafil
Baseline21.372 ± 11.3408
Change at Week 16-6.145 ± 10.3499
SecondaryChange From Baseline in Right Atrial Pressure (RAP) at Week 16

RAP is the blood pressure in the right atrium of the heart. It reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system. RAP was measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position.

Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Right Atrial Pressure (RAP) at Week 16
mmHgSildenafil
Baseline6.5 ± 2.88
Change at Week 161.3 ± 2.36
SecondaryChange From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16

PCWP was measured by pulmonary artery catheterization and provided an indirect measure of left atrial pressure.

Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16
mmHgSildenafil
Baseline8.5 ± 0.84
Change at Week 162.5 ± 1.00
SecondaryChange From Baseline in Cardiac Output (CO) at Week 16

Cardiac output is simply the amount of blood pumped by the heart per minute.

Time frame:
Baseline, Week 16
Reported as:
Mean · liter per minute
Change From Baseline in Cardiac Output (CO) at Week 16
liter per minuteSildenafil
Baseline2.620 ± 0.9879
Change at Week 160.420 ± 0.9076
SecondaryChange From Baseline in Cardiac Index (CI) at Week 16

Cardiac index is a hemodynamic parameter that relates the cardiac output from left ventricle in one minute to BSA, thus relating heart performance to the size of the individual. CI was calculated as cardiac output in systemic circulation divided by BSA.

Time frame:
Baseline, Week 16
Reported as:
Mean · liter per minute per meter square
Change From Baseline in Cardiac Index (CI) at Week 16
liter per minute per meter squareSildenafil
Baseline3.070 ± 0.7460
Change at Week 160.658 ± 1.8912
SecondaryChange From Baseline in Systemic Vascular Resistance (SVR) at Week 16

The resistance to blood flow through the systemic circulation is known as SVR. This can be used in measuring blood pressure, blood flow and cardiac function and measured in terms of Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

Time frame:
Baseline, Week 16
Reported as:
Mean · Wood units
Change From Baseline in Systemic Vascular Resistance (SVR) at Week 16
Wood unitsSildenafil
Baseline26.545 ± 3.0768
Change at Week 16-3.403 ± 4.4409
SecondaryChange From Baseline in Systemic Vascular Resistance Index (SVRI) at Week 16

SVRI equals systemic vascular resistance (SVR) times BSA. SVR is the resistance to blood flow through the systemic circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5).

Time frame:
Baseline, Week 16
Reported as:
Mean · Wood units*meter^2
Change From Baseline in Systemic Vascular Resistance Index (SVRI) at Week 16
Wood units*meter^2Sildenafil
Baseline23.855 ± 12.1480
Change at Week 16-2.378 ± 3.9096
SecondaryChange From Baseline in Mixed Venous Oxygen Saturation (SvO2) at Week 16

SvO2 is the percentage of mixed venous oxygen (amount of oxygen bound to hemoglobin in venous blood). Change from baseline in percentage of mixed venous oxygen was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage of mixed venous oxygen
Change From Baseline in Mixed Venous Oxygen Saturation (SvO2) at Week 16
percentage of mixed venous oxygenSildenafil
Baseline65.30 ± 8.549
Change at Week 165.38 ± 12.426
SecondaryChange From Baseline in Arterial Oxygen Saturation (SaO2) at Week 16

SaO2 is the percentage of arterial oxygen (amount of oxygen bound to hemoglobin in arterial blood). Change from baseline in percentage of arterial oxygen was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage of arterial oxygen
Change From Baseline in Arterial Oxygen Saturation (SaO2) at Week 16
percentage of arterial oxygenSildenafil
Baseline95.08 ± 2.730
Change at Week 16-0.80 ± 1.691
Other pre-specifiedMaximum Observed Plasma Concentration (Cmax) of Sildenafil and UK-103,320

UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Sildenafil and UK-103,320
nanogram per milliliter (ng/mL)Sildenafil
Sildenafil138.1 ± 73
UK-103,32073.66 ± 48
Other pre-specifiedArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Sildenafil and UK-103,320

UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Geometric mean · nanogram*hour per millimeter
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Sildenafil and UK-103,320
nanogram*hour per millimeterSildenafil
Sildenafil338.9 ± 54
UK-103,320210.2 ± 74
Other pre-specifiedTime to Reach Maximum Observed Plasma Concentration (Tmax) of Sildenafil and UK-103,320

UK-103,320 was the main metabolite of Sildenafil and was produced by cytochrome P450 3A4.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sildenafil and UK-103,320
hourSildenafil
Sildenafil1.00 (1.00 to 1.97)
UK-103,3201.00 (1.00 to 1.97)
Other pre-specifiedTerminal Half Life (t1/2) of Sildenafil and UK-103,320

Terminal half-life is the time measured for the plasma concentration to decrease by one half of its original concentration. UK-103,320 was a main metabolite of sildenafil and was produced by cytochrome P450 3A4.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Median · hour
Terminal Half Life (t1/2) of Sildenafil and UK-103,320
hourSildenafil
Sildenafil1.785 (1.63 to 1.94)
UK-103,3202.110 (2.04 to 3.26)
Other pre-specifiedApparent Oral Clearance (CL/F) of Sildenafil

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Geometric mean · liter per hour
Apparent Oral Clearance (CL/F) of Sildenafil
liter per hourSildenafil
Apparent Oral Clearance (CL/F) of Sildenafil41.73 ± 77
Other pre-specifiedApparent Volume of Distribution (Vz/F) of Sildenafil

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Pre-dose (0 hour) on Week 4, 8, 16 and 1, 2, 4, 8 hours post-dose on Week 16
Reported as:
Median · liter
Apparent Volume of Distribution (Vz/F) of Sildenafil
literSildenafil
Apparent Volume of Distribution (Vz/F) of Sildenafil77.90 (62.4 to 93.4)
Other pre-specifiedChange From Baseline in Ratio of Acceleration Time to Ejection Time (AcT/ET) at Week 16

Acceleration time and ejection time are quantitative Doppler parameters and ratio of acceleration time to ejection time is a useful tool to evaluate the severity of aortic stenosis.

Time frame:
Baseline, Week 16
Reported as:
Mean · ratio
Change From Baseline in Ratio of Acceleration Time to Ejection Time (AcT/ET) at Week 16
ratioSildenafil
Baseline0.3038 ± 0.09675
Change at Week 160.0175 ± 0.10261
Other pre-specifiedChange From Baseline in Right Ventricular Tei Index at Week 16

The right ventricular Tei Index is an index of myocardial performance. It is defined as the sum of isovolumic contraction time and isovolumic relaxation time divided by the ejection time.

Time frame:
Baseline, Week 16
Reported as:
Mean · ratio
Change From Baseline in Right Ventricular Tei Index at Week 16
ratioSildenafil
Baseline0.7540 ± 0.48602
Change at Week 16-0.0440 ± 0.37618
Other pre-specifiedChange From Baseline in Right Ventricular Size at Week 16
Time frame:
Baseline, Week 16
Reported as:
Mean · centimeter (cm)
Change From Baseline in Right Ventricular Size at Week 16
centimeter (cm)Sildenafil
Baseline3.37 ± 1.216
Change at Week 16-0.40 ± 0.408
Other pre-specifiedChange From Baseline in Tricuspid Valve Annulus Size at Week 16

The tricuspid valve lies between the right atrium and the right ventricle and is placed in a more apical position than the mitral valve. The annulus separates the right atrium from the right ventricle. Change from baseline in tricuspid valve annulus size (in cm) was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · cm
Change From Baseline in Tricuspid Valve Annulus Size at Week 16
cmSildenafil
Baseline2.190 ± 0.5636
Change at Week 16-0.103 ± 0.3727
Other pre-specifiedChange From Baseline in Tricuspid Regurgitation - Pressure Gradient (TR-PG) Peak at Week 16

Tricuspid regurgitation (insufficiency) is the failure of the tricuspid valve to close properly during systole, leading to the leaking of blood from the right ventricle into the right atrium. Change from baseline in TR-PG peak (in mmHg) was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Tricuspid Regurgitation - Pressure Gradient (TR-PG) Peak at Week 16
mmHgSildenafil
Baseline73.0 ± 39.31
Change at Week 16-6.0 ± 33.94
Other pre-specifiedChange From Baseline in Pulmonary Regurgitation - Pressure Gradient (PR-PG) End-Diastole at Week 16

Pulmonary regurgitation (PR) or insufficiency is a valvular heart disease characterized by an incomplete closure of the pulmonary valve leading to a diastolic reflux into the right ventricle. Change from baseline in PR-PG end-diastole (in mmHg) was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · mmHg
Change From Baseline in Pulmonary Regurgitation - Pressure Gradient (PR-PG) End-Diastole at Week 16
mmHgSildenafil
Baseline29.0 ± 14.73
Change at Week 163.5 ± 13.44
Other pre-specifiedNumber of Participants With Pericardial Effusion

Pericardial effusion is the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Pericardial Effusion
participantsSildenafil
Number of Participants With Pericardial Effusion0
Other pre-specifiedChange From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 16

Tricuspid annular plane systolic excursion is a parameter depicting global right ventricular function. Change from baseline in TAPSE (in cm) was reported in this outcome measure.

Time frame:
Baseline, Week 16
Reported as:
Mean · cm
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 16
cmSildenafil
Baseline1.47 ± 0.437
Change at Week 160.18 ± 0.320

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (maximum duration of treatment: 119.6 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventSildenafil
BronchitisInfections and infestations3/6
NasopharyngitisInfections and infestations3/6
Upper respiratory tract infectionInfections and infestations3/6
DiarrhoeaGastrointestinal disorders2/6
GastroenteritisInfections and infestations2/6
HeadacheNervous system disorders2/6
EpistaxisRespiratory, thoracic and mediastinal disorders2/6
Cardiac failureCardiac disorders1/6
Conjunctivitis allergicEye disorders1/6
Dental cariesGastrointestinal disorders1/6

Baseline characteristics

Efficacy analysis set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Sildenafil
<=18 years6
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Sildenafil
Mean6.7 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Sildenafil
Female3
Male3
08

Study locations

5 sites
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0375, Japan
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
  • Toho University Omori Medical Center
    Ota-ku, Tokyo 143-8541, Japan
  • National Center for Child Health and Development
    Setagaya-ku, Tokyo 157-8535, Japan
  • Shizuoka Children's Hospital
    Shizuoka, 420-8660, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2012 to primary completion in May 2016, 44 months.

Results were first posted in Apr 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2012
First posted
Jul 17, 2012
StartActual
Aug 24, 2012
Primary completionActual
May 20, 2016
CompletionActual
Mar 12, 2018
Results first posted
Apr 4, 2017
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01642407
Responsible party
Sponsor
First posted
Jul 17, 2012
Start date
Aug 24, 2012
Primary completion
May 20, 2016
Completion
Mar 12, 2018
Results posted
Apr 4, 2017
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion